1
|
Osorno LL, Brandley AN, Maldonado DE, Yiantsos A, Mosley RJ, Byrne ME. Review of Contemporary Self-Assembled Systems for the Controlled Delivery of Therapeutics in Medicine. NANOMATERIALS (BASEL, SWITZERLAND) 2021; 11:278. [PMID: 33494400 PMCID: PMC7911285 DOI: 10.3390/nano11020278] [Citation(s) in RCA: 35] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 01/12/2021] [Accepted: 01/15/2021] [Indexed: 12/12/2022]
Abstract
The novel and unique design of self-assembled micro and nanostructures can be tailored and controlled through the deep understanding of the self-assembly behavior of amphiphilic molecules. The most commonly known amphiphilic molecules are surfactants, phospholipids, and block copolymers. These molecules present a dual attraction in aqueous solutions that lead to the formation of structures like micelles, hydrogels, and liposomes. These structures can respond to external stimuli and can be further modified making them ideal for specific, targeted medical needs and localized drug delivery treatments. Biodegradability, biocompatibility, drug protection, drug bioavailability, and improved patient compliance are among the most important benefits of these self-assembled structures for drug delivery purposes. Furthermore, there are numerous FDA-approved biomaterials with self-assembling properties that can help shorten the approval pathway of efficient platforms, allowing them to reach the therapeutic market faster. This review focuses on providing a thorough description of the current use of self-assembled micelles, hydrogels, and vesicles (polymersomes/liposomes) for the extended and controlled release of therapeutics, with relevant medical applications. FDA-approved polymers, as well as clinically and commercially available nanoplatforms, are described throughout the paper.
Collapse
Affiliation(s)
| | | | | | | | | | - Mark E. Byrne
- Biomimetic & Biohybrid Materials, Biomedical Devices, & Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, Glassboro, NJ 08028, USA
| |
Collapse
|
2
|
Asadpour S, Yeganeh H, Khademi F, Ghanbari H, Ai J. Resveratrol-loaded polyurethane nanofibrous scaffold: viability of endothelial and smooth muscle cells. Biomed Mater 2019; 15:015001. [DOI: 10.1088/1748-605x/ab4e23] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
3
|
Wan S, Zhang L, Quan Y, Wei K. Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy. ROYAL SOCIETY OPEN SCIENCE 2018; 5:181457. [PMID: 30564426 PMCID: PMC6281916 DOI: 10.1098/rsos.181457] [Citation(s) in RCA: 71] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/01/2018] [Accepted: 10/16/2018] [Indexed: 05/25/2023]
Abstract
Resveratrol (3, 4', 5-trihydroxy-trans-stilbene, RSV), a nutraceutical, has recently attracted lots of attention because of its outstanding pharmacological potential. The effects of RSV on non-alcoholic fatty liver disease (NAFLD) remain inconclusive, although a wealth of research has been done. The major obstacle presented was RSV's poor bioavailability due to its poor aqueous solubility, chemical instability and intestinal metabolism. In this study, nanotechnology was used to encapsulate RSV to enhance its stability, water solubility and bioactivity, which can be used to treat NAFLD by HepG2 hepatocytes-induced in vitro. RSV-loaded poly (d, l-lactide-co-glycolide acid) (PLGA) nanoparticles (RSV-PLGA-NPs) were prepared according to an oil/water (O/W) emulsion technique. The RSV-PLGA-NPs were of spherical morphology with an average size of 176.1 nm and a negative charge of -22.6 mV. These nanoparticles exhibited remarkable encapsulation efficiency (EE%) (97.25%) and drug loading (14.9%) for RSV. A sustained RSV release from RSV-PLGA-NPs could be achieved especially in acidic conditions when simulating transporting through the gastrointestinal tract. In addition, these nanoparticles were stable enough to store at 4°C for a least six months with unchanged EE%. Moreover, RSV-PLGA-NPs were more efficient in alleviating lipogenesis, promoting lipolysis and reducing hepatocellular proliferation than free RSV due to its improved stability, water solubility and bioactivity. These findings indicated that the RSV-PLGA-NPs provided superb and stable drug delivery with small particle size, high capsulation efficiency, well-controlled drug release, which greatly enhanced the stability, water solubility and bioactivity. Besides, the discovery that the inhibitory effect of RSV-PLGA-NPs on hepatocellular proliferation and lipid accumulation in steatotic HepG2 cells may provide a new way to study the mechanism of NAFLD. Therefore, RSV-PLGA-NPs have a promising potential for NAFLD therapy.
Collapse
Affiliation(s)
- Shuqian Wan
- School of Biological Science and Engineering, South China University of Technology, Guangzhou 510640, People's Republic of China
| | - Long Zhang
- Wenzhou Institute of Biomaterials and Engineering, CAS, Wenzhou, Zhejiang 325011, People's Republic of China
| | - Yunyun Quan
- Wenzhou Institute of Biomaterials and Engineering, CAS, Wenzhou, Zhejiang 325011, People's Republic of China
| | - Kun Wei
- School of Biological Science and Engineering, South China University of Technology, Guangzhou 510640, People's Republic of China
- Wenzhou Institute of Biomaterials and Engineering, CAS, Wenzhou, Zhejiang 325011, People's Republic of China
| |
Collapse
|
4
|
Wang P, Li Y, Jiang M. Effects of the multilayer structures on Exenatide release and bioactivity in microsphere/thermosensitive hydrogel system. Colloids Surf B Biointerfaces 2018; 171:85-93. [PMID: 30015142 DOI: 10.1016/j.colsurfb.2018.04.063] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Revised: 04/28/2018] [Accepted: 04/30/2018] [Indexed: 02/08/2023]
Abstract
Traditional polypeptide-loaded PLGA microspheres (PM) using emulsion electrospray techniques often exhibit unsteady release and limited bioactivity. To solve these two problems, an Exenatide (EXT)-loaded multilayer system composed ofPM and thermosensitive hydrogel was prepared by the emulsion electrospray technique in this study. Hydrogel mixture were loaded in PLGA microspheres as Depot-hydrogel to prepare Gel/PM. The PM/Gel and Gel/PM/Gel systems were obtained by dispersion of PM and Gel/PM into hydrogel mixture, respectively. EXT in Gel/PM/Gel showed a constantly in vitro release for 30 days, which was significantly enhanced in comparison of those in the PM/Gel and the Gel/PM. PM/Gel and Gel/PM/Gel showed diminished burst release and no platform period compared with PM and Gel/PM. And these could be because the introduced Matrix-hydrogel outside, as a buffer layer, inhibited burst releases and exhibited a sustained manner. The inner Depot-hydrogelstructure slowed the PLGA degradation rate and drug release rate. As well, more than 15-day blood glucose levels in KKAy mice were greatly maintained at 7.50-9.50 mmol/L after a single subcutaneous injection of Gel/PM/Gel (4.95 μg/kg). Spatial stability and further bioactivity of released EXT were well protected by EXT-hydrogel complexes, and undesirable uptake of EXT and microspheres via phagocytes were also decreased by PEG shell. Thus, the long-acting microspheres/hydrogel multilayer system prepared by emulsion electrospray technique showed promising potentials for loading hydrophilic polypeptides and proteins.
Collapse
Affiliation(s)
- Puxiu Wang
- Department of Pharmacy, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China; Department of the First Clinical Pharmacy, China Medical University, Shenyang, Liaoning, PR China.
| | - Yue Li
- Department of Pharmacy, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China.
| | - Mingyan Jiang
- Department of Pharmacy, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China.
| |
Collapse
|
5
|
Chakroun RW, Zhang P, Lin R, Schiapparelli P, Quinones-Hinojosa A, Cui H. Nanotherapeutic systems for local treatment of brain tumors. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2017; 10. [PMID: 28544801 DOI: 10.1002/wnan.1479] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Revised: 04/14/2017] [Accepted: 04/18/2017] [Indexed: 12/31/2022]
Abstract
Malignant brain tumor, including the most common type glioblastoma, are histologically heterogeneous and invasive tumors known as the most devastating neoplasms with high morbidity and mortality. Despite multimodal treatment including surgery, radiotherapy, chemotherapy, and immunotherapy, the disease inevitably recurs and is fatal. This lack of curative options has motivated researchers to explore new treatment strategies and to develop new drug delivery systems (DDSs); however, the unique anatomical, physiological, and pathological features of brain tumors greatly limit the effectiveness of conventional chemotherapy. In this context, we review the recent progress in the development of nanoparticle-based DDSs aiming to address the key challenges in transporting sufficient amount of therapeutic agents into the brain tumor areas while minimizing the potential side effects. We first provide an overview of the standard treatments currently used in the clinic for the management of brain cancers, discussing the effectiveness and limitations of each therapy. We then provide an in-depth review of nanotherapeutic systems that are intended to bypass the blood-brain barrier, overcome multidrug resistance, infiltrate larger tumorous tissue areas, and/or release therapeutic agents in a controlled manner. WIREs Nanomed Nanobiotechnol 2018, 10:e1479. doi: 10.1002/wnan.1479 This article is categorized under: Implantable Materials and Surgical Technologies > Nanomaterials and Implants Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
Collapse
Affiliation(s)
- Rami Walid Chakroun
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA
| | - Pengcheng Zhang
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA
| | - Ran Lin
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA
| | | | | | - Honggang Cui
- Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA
| |
Collapse
|
6
|
Mylonaki I, Allémann É, Saucy F, Haefliger JA, Delie F, Jordan O. Perivascular medical devices and drug delivery systems: Making the right choices. Biomaterials 2017; 128:56-68. [PMID: 28288349 DOI: 10.1016/j.biomaterials.2017.02.028] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2016] [Revised: 02/13/2017] [Accepted: 02/26/2017] [Indexed: 12/31/2022]
Abstract
Perivascular medical devices and perivascular drug delivery systems are conceived for local application around a blood vessel during open vascular surgery. These systems provide mechanical support and/or pharmacological activity for the prevention of intimal hyperplasia following vessel injury. Despite abundant reports in the literature and numerous clinical trials, no efficient perivascular treatment is available. In this review, the existing perivascular medical devices and perivascular drug delivery systems, such as polymeric gels, meshes, sheaths, wraps, matrices, and metal meshes, are jointly evaluated. The key criteria for the design of an ideal perivascular system are identified. Perivascular treatments should have mechanical specifications that ensure system localization, prolonged retention and adequate vascular constriction. From the data gathered, it appears that a drug is necessary to increase the efficacy of these systems. As such, the release kinetics of pharmacological agents should match the development of the pathology. A successful perivascular system must combine these optimized pharmacological and mechanical properties to be efficient.
Collapse
Affiliation(s)
- Ioanna Mylonaki
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
| | - Éric Allémann
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
| | - François Saucy
- Department of Vascular Surgery, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne, Switzerland
| | - Jacques-Antoine Haefliger
- Department of Vascular Surgery, Lausanne University Hospital, rue du Bugnon 46, CH-1011 Lausanne, Switzerland
| | - Florence Delie
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
| | - Olivier Jordan
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.
| |
Collapse
|
7
|
Wang P, Chu W, Zhuo X, Zhang Y, Gou J, Ren T, He H, Yin T, Tang X. Modified PLGA–PEG–PLGA thermosensitive hydrogels with suitable thermosensitivity and properties for use in a drug delivery system. J Mater Chem B 2017; 5:1551-1565. [DOI: 10.1039/c6tb02158a] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
PLGA–PEG–PLGA (PPP) triblock copolymer is the most widely studied thermosensitive hydrogel owing to its non-toxic, biocompatible, biodegradable, and thermosensitive properties.
Collapse
Affiliation(s)
- Puxiu Wang
- Department of Pharmaceutics
- Shenyang Pharmaceutical University
- Shenyang
- China
| | - Wei Chu
- Department of Pharmaceutics
- Shenyang Pharmaceutical University
- Shenyang
- China
| | - Xuezhi Zhuo
- Department of Pharmaceutics
- Shenyang Pharmaceutical University
- Shenyang
- China
| | - Yu Zhang
- Department of Pharmaceutics
- Shenyang Pharmaceutical University
- Shenyang
- China
| | - Jingxin Gou
- Department of Pharmaceutics
- Shenyang Pharmaceutical University
- Shenyang
- China
| | - Tianyang Ren
- Department of Pharmaceutics
- Shenyang Pharmaceutical University
- Shenyang
- China
| | - Haibing He
- Department of Pharmaceutics
- Shenyang Pharmaceutical University
- Shenyang
- China
| | - Tian Yin
- School of Functional Food and Wine
- Shenyang Pharmaceutical University
- Shenyang
- China
| | - Xing Tang
- Department of Pharmaceutics
- Shenyang Pharmaceutical University
- Shenyang
- China
| |
Collapse
|
8
|
Mylonaki I, Strano F, Deglise S, Allémann E, Alonso F, Corpataux JM, Dubuis C, Haefliger JA, Jordan O, Saucy F, Delie F. Perivascular sustained release of atorvastatin from a hydrogel-microparticle delivery system decreases intimal hyperplasia. J Control Release 2016; 232:93-102. [DOI: 10.1016/j.jconrel.2016.04.023] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Revised: 04/13/2016] [Accepted: 04/14/2016] [Indexed: 12/26/2022]
|
9
|
Liow SS, Dou Q, Kai D, Karim AA, Zhang K, Xu F, Loh XJ. Thermogels: In Situ Gelling Biomaterial. ACS Biomater Sci Eng 2016; 2:295-316. [DOI: 10.1021/acsbiomaterials.5b00515] [Citation(s) in RCA: 144] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Sing Shy Liow
- Institute of Materials Research and Engineering (IMRE), 2 Fusionopolis Way, #08-03 Innovis, Singapore 138634
| | - Qingqing Dou
- Institute of Materials Research and Engineering (IMRE), 2 Fusionopolis Way, #08-03 Innovis, Singapore 138634
| | - Dan Kai
- Institute of Materials Research and Engineering (IMRE), 2 Fusionopolis Way, #08-03 Innovis, Singapore 138634
| | - Anis Abdul Karim
- Institute of Materials Research and Engineering (IMRE), 2 Fusionopolis Way, #08-03 Innovis, Singapore 138634
| | - Kangyi Zhang
- Institute of Materials Research and Engineering (IMRE), 2 Fusionopolis Way, #08-03 Innovis, Singapore 138634
| | | | - Xian Jun Loh
- Institute of Materials Research and Engineering (IMRE), 2 Fusionopolis Way, #08-03 Innovis, Singapore 138634
- Department
of Materials Science and Engineering, National University of Singapore, 9 Engineering Drive 1, Singapore 117576, Singapore
- Singapore Eye Research Institute, 11 Third Hospital Avenue, Singapore 168751, Singapore
| |
Collapse
|
10
|
Mountziaris PM, Shah SR, Lam J, Bennett GN, Mikos AG. A rapid, flexible method for incorporating controlled antibiotic release into porous polymethylmethacrylate space maintainers for craniofacial reconstruction. Biomater Sci 2016; 4:121-9. [PMID: 26340063 PMCID: PMC4679697 DOI: 10.1039/c5bm00175g] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Severe injuries in the craniofacial complex, resulting from trauma or pathology, present several challenges to functional and aesthetic reconstruction. The anatomy and position of the craniofacial region make it vulnerable to injury and subsequent local infection due to external bacteria as well as those from neighbouring structures like the sinuses, nasal passages, and mouth. Porous polymethylmethacrylate (PMMA) "space maintainers" have proven useful in staged craniofacial reconstruction by promoting healing of overlying soft tissue prior to reconstruction of craniofacial bones. We describe herein a method by which the porosity of a prefabricated porous PMMA space maintainer, generated by porogen leaching, can be loaded with a thermogelling copolymer-based drug delivery system. Porogen leaching, space maintainer prewetting, and thermogel loading all significantly affected the loading of a model antibiotic, colistin. Weeks-long release of antibiotic at clinically relevant levels was achieved with several formulations. In vitro assays confirmed that the released colistin maintained its antibiotic activity against several bacterial targets. Our results suggest that this method is a valuable tool in the development of novel therapeutic approaches for the treatment of severe complex, infected craniofacial injuries.
Collapse
Affiliation(s)
- P M Mountziaris
- Department of Bioengineering, Rice University, Houston, Texas, USA. and Division of Plastic Surgery, Albany Medical Center, Albany, NY, USA
| | - S R Shah
- Department of Bioengineering, Rice University, Houston, Texas, USA.
| | - J Lam
- Department of Bioengineering, Rice University, Houston, Texas, USA.
| | - G N Bennett
- Department of BioSciences, Rice University, Houston, Texas, USA.
| | - A G Mikos
- Department of Bioengineering, Rice University, Houston, Texas, USA.
| |
Collapse
|
11
|
Punnakitikashem P, Truong D, Menon JU, Nguyen KT, Hong Y. Electrospun biodegradable elastic polyurethane scaffolds with dipyridamole release for small diameter vascular grafts. Acta Biomater 2014; 10:4618-4628. [PMID: 25110284 DOI: 10.1016/j.actbio.2014.07.031] [Citation(s) in RCA: 83] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2014] [Revised: 07/22/2014] [Accepted: 07/30/2014] [Indexed: 12/20/2022]
Abstract
Acellular biodegradable small diameter vascular grafts (SDVGs) require antithrombosis, intimal hyperplasia inhibition and rapid endothelialization to improve the graft patency. However, current antithrombosis and antiproliferation approaches often conflict with endothelial cell layer formation on SDVGs. To address this limitation, biodegradable elastic polyurethane urea (BPU) and the drug dipyridamole (DPA) were mixed and then electrospun into a biodegradable fibrous scaffold. The BPU would provide the appropriate mechanical support, while the DPA in the scaffold would offer biofunctions as required above. We found that the resulting scaffolds had tensile strengths and strains comparable with human coronary artery. The DPA in the scaffolds was continuously released up to 91 days in phosphate buffer solution at 37 °C, with a low burst release within the first 3 days. Compared to BPU alone, improved non-thrombogenicity of the DPA-loaded BPU scaffolds was evidenced with extended human blood clotting time, lower TAT complex concentration, lower hemolysis and reduced human platelet deposition. The scaffolds with a higher DPA content (5 and 10%) inhibited proliferation of human aortic smooth muscle cell significantly. Furthermore, the DPA-loaded scaffolds had no adverse effect on human aortic endothelial cell growth, yet it improved their proliferation. The attractive mechanical properties and biofunctions of the DPA-loaded BPU scaffold indicate its potential as an acellular biodegradable SDVG for vascular replacement.
Collapse
Affiliation(s)
- Primana Punnakitikashem
- Department of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA; Joint Biomedical Engineering Program, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Danh Truong
- Department of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA; Joint Biomedical Engineering Program, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Jyothi U Menon
- Department of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA; Joint Biomedical Engineering Program, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Kytai T Nguyen
- Department of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA; Joint Biomedical Engineering Program, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Yi Hong
- Department of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA; Joint Biomedical Engineering Program, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
| |
Collapse
|
12
|
Release behavior and antibiofilm activity of usnic acid-loaded carboxylated poly(l-lactide) microparticles. Eur J Pharm Biopharm 2014; 88:415-23. [DOI: 10.1016/j.ejpb.2014.06.002] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2014] [Revised: 05/30/2014] [Accepted: 06/02/2014] [Indexed: 02/07/2023]
|
13
|
Shi X, Chen G, Guo LW, Si Y, Zhu M, Pilla S, Liu B, Gong S, Kent KC. Periadventitial application of rapamycin-loaded nanoparticles produces sustained inhibition of vascular restenosis. PLoS One 2014; 9:e89227. [PMID: 24586612 PMCID: PMC3931710 DOI: 10.1371/journal.pone.0089227] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2013] [Accepted: 01/16/2014] [Indexed: 01/20/2023] Open
Abstract
Open vascular reconstructions frequently fail due to the development of recurrent disease or intimal hyperplasia (IH). This paper reports a novel drug delivery method using a rapamycin-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs)/pluronic gel system that can be applied periadventitially around the carotid artery immediately following the open surgery. In vitro studies revealed that rapamycin dispersed in pluronic gel was rapidly released over 3 days whereas release of rapamycin from rapamycin-loaded PLGA NPs embedded in pluronic gel was more gradual over 4 weeks. In cultured rat vascular smooth muscle cells (SMCs), rapamycin-loaded NPs produced durable (14 days versus 3 days for free rapamycin) inhibition of phosphorylation of S6 kinase (S6K1), a downstream target in the mTOR pathway. In a rat balloon injury model, periadventitial delivery of rapamycin-loaded NPs produced inhibition of phospho-S6K1 14 days after balloon injury. Immunostaining revealed that rapamycin-loaded NPs reduced SMC proliferation at both 14 and 28 days whereas rapamycin alone suppressed proliferation at day 14 only. Moreover, rapamycin-loaded NPs sustainably suppressed IH for at least 28 days following treatment, whereas rapamycin alone produced suppression on day 14 with rebound of IH by day 28. Since rapamycin, PLGA, and pluronic gel have all been approved by the FDA for other human therapies, this drug delivery method could potentially be translated into human use quickly to prevent failure of open vascular reconstructions.
Collapse
Affiliation(s)
- Xudong Shi
- Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States of America
| | - Guojun Chen
- Wisconsin Institutes for Discovery, University of Wisconsin, Madison, Wisconsin, United States of America ; Materials Science Program, University of Wisconsin, Madison, Wisconsin, United States of America
| | - Lian-Wang Guo
- Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States of America
| | - Yi Si
- Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States of America
| | - Men Zhu
- Wisconsin Institutes for Discovery, University of Wisconsin, Madison, Wisconsin, United States of America ; Materials Science Program, University of Wisconsin, Madison, Wisconsin, United States of America
| | - Srikanth Pilla
- Wisconsin Institutes for Discovery, University of Wisconsin, Madison, Wisconsin, United States of America
| | - Bo Liu
- Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States of America
| | - Shaoqin Gong
- Wisconsin Institutes for Discovery, University of Wisconsin, Madison, Wisconsin, United States of America ; Materials Science Program, University of Wisconsin, Madison, Wisconsin, United States of America ; Department of Biomedical Engineering, University of Wisconsin, Madison, Wisconsin, United States of America
| | - K Craig Kent
- Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States of America
| |
Collapse
|
14
|
McClure M, Wolfe P, Rodriguez I, Bowlin G. Bioengineered vascular grafts: improving vascular tissue engineering through scaffold design. J Drug Deliv Sci Technol 2011. [DOI: 10.1016/s1773-2247(11)50030-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
15
|
Javanbakht M, Mohammadi S, Esfandyari-Manesh M, Abdouss M. Molecularly imprinted polymer microspheres with nanopore cavities prepared by precipitation polymerization as new carriers for the sustained release of dipyridamole. J Appl Polym Sci 2010. [DOI: 10.1002/app.32798] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
16
|
Owen SC, Li H, Sanders WG, Cheung AK, Terry CM. Correlation of tissue drug concentrations with in vivo magnetic resonance images of polymer drug depot around arteriovenous graft. J Control Release 2010; 146:23-30. [PMID: 20457189 DOI: 10.1016/j.jconrel.2010.05.005] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2009] [Revised: 03/18/2010] [Accepted: 05/04/2010] [Indexed: 12/15/2022]
Abstract
Sustained delivery of anti-proliferative drugs to the perivascular area using an injectable polymeric platform is a strategy to inhibit vascular hyperplasia and stenosis. In this study, the concentrations of sirolimus in vascular tissues were evaluated after delivery using an injectable platform made of poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid) (PLGA-PEG-PLGA). In order to optimize the drug release profile, the effect of two solvents or solid loading of the sirolimus into the polymer gel was first examined in vitro. The early release was slower with loading of dry drug into the polymer, compared to drug dissolution in solvents. Dry sirolimus was therefore used to load the polymer and applied to the perivascular surface of the graft-venous anastomosis at the time of surgical placement of a carotid-jugular synthetic hemodialysis graft in a porcine model. This was replenished by ultrasound-guided injection of additional drug-laden polymer at one, two and three weeks post-operatively. Magnetic resonance imaging (MRI) using pulse sequences specifically designed for optimal detection of the polymeric gel showed that the polymer injected post-operatively remained at the juxta-anastomotic perivascular site at two weeks. Sirolimus was extracted from various segments of the juxta-anastomotic tissues and the drug concentrations were determined using HPLC MS/MS. Tissue sirolimus concentrations at one and two weeks were highest near the venous anastomosis, which were approximately 100- to 500-fold greater than the concentrations necessary to inhibit vascular smooth muscle cell proliferation in vitro. Drug concentrations remained above the inhibitory concentrations for at least six weeks post-operatively. Thus, serial injections of sustained-delivery polymer gel loaded with sirolimus can provide high localized concentrations at target vascular tissues and thus may be useful for the prevention and treatment of vascular proliferative disorders such as hemodialysis graft stenosis. In addition, MRI is useful for the monitoring of the location of the drug depot.
Collapse
Affiliation(s)
- Shawn C Owen
- Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, 301 Skaggs Hall, 30 South 2000 East, Salt Lake City, UT 84112, USA
| | | | | | | | | |
Collapse
|
17
|
Lü JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, Chen C. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 2009; 9:325-41. [PMID: 19435455 DOI: 10.1586/erm.09.15] [Citation(s) in RCA: 564] [Impact Index Per Article: 37.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Co-polymer poly(lactic-co-glycolic acid) (PLGA) nanotechnology has been developed for many years and has been approved by the US FDA for the use of drug delivery, diagnostics and other applications of clinical and basic science research, including cardiovascular disease, cancer, vaccine and tissue engineering. This article presents the more recent successes of applying PLGA-based nanotechnologies and tools in these medicine-related applications. It focuses on the possible mechanisms, diagnosis and treatment effects of PLGA preparations and devices. This updated information will benefit to both new and established research scientists and clinical physicians who are interested in the development and application of PLGA nanotechnology as new therapeutic and diagnostic strategies for many diseases.
Collapse
Affiliation(s)
- Jian-Ming Lü
- Michael E DeBakey Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, Baylor College of Medicine, Houston, TX 77030, USA
| | | | | | | | | | | | | |
Collapse
|
18
|
Livshits VA, Bonartsev AP, Iordanskii AL, Ivanov EA, Makhina TA, Myshkina VL, Bonartseva GA. Microspheres based on poly(3-hydroxy)butyrate for prolonged drug release. POLYMER SCIENCE SERIES B 2009. [DOI: 10.1134/s1560090409070082] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
19
|
Elstad NL, Fowers KD. OncoGel (ReGel/paclitaxel)--clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev 2009; 61:785-94. [PMID: 19422870 DOI: 10.1016/j.addr.2009.04.010] [Citation(s) in RCA: 179] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2008] [Accepted: 04/28/2009] [Indexed: 10/20/2022]
Abstract
Cancer treatment regimens often include multiple anticancer agents targeting different cellular mechanisms in delicate balance with associated toxicity. Drug delivery systems offer a unique tool in the treatment of cancer, and applications in the local treatment of cancer have demonstrated utility in providing sustained high local concentrations at the tumor site while minimizing systemic drug levels. Treatment options for local cancer therapy are focused on indications where targeted activity may result in improved patient outcomes such as increased local control and decreased metastatic potential. Targeted therapies may also enhance response to combination anticancer regimens. OncoGel, a controlled-release depot formulation of paclitaxel in ReGel, has been evaluated in numerous nonclinical studies. Results from these studies demonstrated OncoGel's ability to physically target paclitaxel to the tumor site with very little reaching the circulation, resulting in an acceptable safety profile with dose-limiting toxicities being local in nature. In addition, OncoGel demonstrated efficacy as a stand-alone treatment and synergistic activity in combination therapies. Clinical studies in superficially-palpable tumors and esophageal carcinoma confirmed local paclitaxel release from OncoGel in patients. OncoGel's ability to improve current treatment options for esophageal and brain cancers is being further evaluated.
Collapse
|
20
|
Yoncheva K, Lambov N, Miloshev S. Modification of Biodegradable Poly(Malate) and Poly(Lactic-co-Glycolic Acid) Microparticles with Low Molecular Polyethylene Glycol. Drug Dev Ind Pharm 2009; 35:449-54. [DOI: 10.1080/03639040802438357] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
21
|
Karst D, Yang Y. Method for predicting sorption of small drug molecules onto polylactide. J Biomed Mater Res A 2009; 88:255-63. [DOI: 10.1002/jbm.a.31882] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
22
|
Bikram M, West JL. Thermo-responsive systems for controlled drug delivery. Expert Opin Drug Deliv 2008; 5:1077-91. [DOI: 10.1517/17425247.5.10.1077] [Citation(s) in RCA: 126] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
23
|
Cheung AK, Terry C, Li L. Pathogenesis and local drug delivery for prevention of vascular access stenosis. J Ren Nutr 2008; 18:140-5. [PMID: 18089461 DOI: 10.1053/j.jrn.2007.10.028] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
A well-functioning vascular access is essential for hemodialysis in end-stage kidney disease patients. Synthetic grafts are more prone to the development of stenosis than native fistulas. Most of the stenosis is caused by neointimal hyperplasia localized at the outflow tract, which is perpetuated by continuous stimuli, such as blood flow disturbance, graft material bioincompatibility, and repeated needle puncture. Hyperplasia formation is also enhanced by the trauma of angioplasty. Recent work suggests that angiogenesis and the migration and proliferation of fibroblasts in the adventitia are important for the pathogenesis of neointimal hyperplasia. Therefore, the perivascular sustained delivery of antiproliferative drugs is a rational approach to inhibit hyperplasia associated with hemodialysis grafts. Because of the chronic nature of the stimuli, strategies that allow for the ready replenishment of the drug depot are preferable and are currently under development.
Collapse
Affiliation(s)
- Alfred K Cheung
- Veterans Affair Salt Lake City Healthcare System, Salt Lake City, Utah, USA.
| | | | | |
Collapse
|
24
|
Zhuplatov SB, Masaki T, Blumenthal DK, Cheung AK. Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation. Basic Clin Pharmacol Toxicol 2007; 99:431-9. [PMID: 17169124 DOI: 10.1111/j.1742-7843.2006.pto_516.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Dipyridamole is a potential pharmacological agent to prevent vascular stenosis because of its antiproliferative properties. The mechanisms by which dipyridamole inhibits the growth of vascular smooth muscle cells, especially venous smooth muscle cells, are unclear. In the present study, dipyridamole transiently but significantly increased cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) levels in human venous and arterial smooth muscle cells in a time- and dose-dependent manner. Peak concentrations of both cyclic nucleotides were achieved at 15-30 min. and correlated with inhibition of proliferation in both cell types. The antiproliferative effects of dipyridamole observed at 48 hr were similar whether drug exposure was only 15 min. or sustained for 48 hr. Specific competitive inhibitors of protein kinases A and G attenuated the antiproliferative effects of subsaturating concentrations of dipyridamole, with the effects of protein kinase inhibition being particularly pronounced in venous smooth muscle cells. Flow cytometry analysis showed that dipyridamole caused an enrichment of cells in G(0)/G(1) and a corresponding reduction of cells in S phase. These data indicate that a transient increase in cGMP and cAMP is sufficient to induce downstream kinase activation and subsequent cell cycle arrest, and that protein kinase G may be more important than protein kinase A in mediating the growth inhibitory effect of dipyridamole in venous protein kinase.
Collapse
Affiliation(s)
- Sergey B Zhuplatov
- Veterans Affairs Salt Lake City Healthcare System, Departments of Medicine, Pharmacology & Toxicology, and Biochemistry, University of Utah, Salt Lake City, Utah, USA
| | | | | | | |
Collapse
|
25
|
Bonartsev AP, Bonartseva GA, Makhina TK, Myshkina VL, Luchinina ES, Livshits VA, Boskhomdzhiev AP, Markin VS, Iordanskii AL. New poly(3-hydroxybutyrate)-based systems for controlled release of dipyridamole and indomethacin. APPL BIOCHEM MICRO+ 2006. [DOI: 10.1134/s0003683806060159] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
26
|
Zhu W, Masaki T, Cheung AK, Kern SE. Cellular pharmacokinetics and pharmacodynamics of dipyridamole in vascular smooth muscle cells. Biochem Pharmacol 2006; 72:956-64. [PMID: 16939681 DOI: 10.1016/j.bcp.2006.07.027] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2006] [Revised: 07/26/2006] [Accepted: 07/26/2006] [Indexed: 11/25/2022]
Abstract
Hemodialysis arteriovenous grafts are often plagued by stenosis at the vein-graft anastomosis, which is due to the proliferation of venous smooth muscle cells (SMCs). Perivascular delivery of dipyridamole, a potent antiproliferative agent, has been proposed for the prevention of graft stenosis. In order to develop an optimal delivery system for dipyridamole, we examined its pharmacokinetics and pharmacodynamics in human and porcine venous and arterial SMCs in vitro. SMCs were incubated with dipyridamole for various durations, and visualized for the uptake and release by fluorescence microscopy, which were further quantified by fluorospectrometry. The antiproliferative effect of dipyridamole was examined by cell counting or the methylthiazoletetrazolium (MTT) dye-reduction assay. Cytotoxicity was examined by the lactate dehydrogenase (LDH)-release assay. The kinetics of dipyridamole transport through the cell membrane was compatible with a passive diffusion mechanism. Dipyridamole inhibited SMC proliferation in a dose-dependent manner and was more effective in venous than arterial cells in both species. The inhibition was completely reversible at 15microg/ml upon drug removal from the medium. At 25microg/ml, however, the effect was partially irreversible, which might be attributed to the cytotoxicity of dipyridamole. These data support the need for sustained delivery of dipyridamole to achieve the long-term inhibition of SMC proliferation in the prevention of stenosis since SMCs are continuously stimulated at the anastomosis of hemodialysis arteriovenous grafts.
Collapse
Affiliation(s)
- Weiwei Zhu
- Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84108, USA
| | | | | | | |
Collapse
|
27
|
Kuji T, Masaki T, Goteti K, Li L, Zhuplatov S, Terry CM, Zhu W, Leypoldt JK, Rathi R, Blumenthal DK, Kern SE, Cheung AK. Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis. Kidney Int 2006; 69:2179-85. [PMID: 16672912 DOI: 10.1038/sj.ki.5000383] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Perivascular delivery of antiproliferative drugs has been proposed as an approach to prevent neointimal hyperplasia associated with hemodialysis polytetrafluoroethylene (PTFE) grafts. We examined this approach to deliver dipyridamole in a porcine graft model. PTFE grafts were implanted between the carotid artery and external jugular vein bilaterally in pigs. During the surgery or 1 week post-graft placement, dipyridamole (0.26-52 mg) alone or incorporated in microspheres was mixed with an injectable polymeric gel and applied to the graft-arterial and graft-venous anastomoses on one side, whereas the contralateral control graft received no treatment. Three or four weeks after operation, the grafts and adjacent vessels were explanted en bloc and cross-sections of the anastomoses were examined histologically. The degree of neointimal hyperplasia was quantified by planimetry. In separate experiments, dipyridamole was extracted from the explanted tissues and assayed by spectrofluorometry. The normalized median hyperplasia areas of the treated and control graft-venous anastomoses were 0.45 (25th-75th percentile, 0.30-0.86) and 0.24 (0.21-0.30), respectively (N=7; P=0.08). The median hyperplasia areas of the treated and control graft-arterial anastomoses were 0.12 (0.07-0.39) and 0.11 (0.09-0.13), respectively (N=7; P=0.31). The dipyridamole levels in the vascular walls around the anastomoses were at or above the in vitro inhibitory concentrations for approximately 3 weeks. These results suggest that the local perivascular sustained delivery of dipyridamole, even at high dosages, was ineffective in inhibiting neointimal hyperplasia associated with PTFE grafts in a porcine model.
Collapse
Affiliation(s)
- T Kuji
- Department of Medicine, University of Utah, Salt Lake City, Utah 84112, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|